Delivery Order SPE2DB22D2206-SPE2DB25FJD29
- Not listed
- The Defense Logistics Agency awarded a $6,530.16 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Mounjaro 12.5 mg/0.5 mL pen injectors, with completion targeted for July 21, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The product will be performed and delivered from the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,644.62 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on July 25, 2025, with a completion date of July 28, 2025. This is a firm fixed-price, non-competitive delivery order with no set-aside designation, issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award represents a standard pharmaceutical procurement supporting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pen injectors on June 2, 2025, with a completion date of June 3, 2025. This competitively awarded, firm fixed-price delivery order represents a supply of the diabetes medication to support federal healthcare needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,769.69 to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pen injectors on August 22, 2025, with completion expected by August 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers the supply of this diabetes medication, which falls within...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,773.80 to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pen injections on August 20, 2025, with completion by August 21, 2025. This firm fixed-price delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), represents a non-competitive set-aside award for a pharmaceutical product commonly used in diabetes management. The...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $1,401.59 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pen injectors. The award, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-competitive delivery order under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,343.84 to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 ml pen injectors on September 10, 2025, with completion scheduled for September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of...
- The Defense Logistics Agency (DLA) awarded a $1,360.45 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,360.45 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 ml pen injectors. This firm fixed-price delivery order, issued on September 3, 2025, represents a non-set-aside, competitively awarded contract with an ultimate completion date of September 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency (DLA) awarded a $2,665.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pen injectors on August 13, 2025, with completion scheduled for August 14, 2025. This award was not set-aside and was competitively awarded to the prime contractor, which maintains its corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJD29Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,265.08 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injectors on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a single delivery transaction for this diabetes medication as part of the company's pharmaceutical supply operations supporting federal healthcare programs. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling value through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement across the Defense Health Agency and other government healthcare systems. The SPE2DX contract functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 7/29/25 |